Literature DB >> 17133094

The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways.

Samuel Wormald1, Douglas J Hilton.   

Abstract

PURPOSE OF REVIEW: Suppressor of cytokine signaling proteins are key regulators of the response of myeloid cells to cytokines and other extracellular stimuli. This review explores recent developments that have shed light on how two of the best-characterized suppressor of cytokine signaling proteins, SOCS1 and SOCS3, attenuate myeloid signaling pathways that lead to inflammation, hematological malignancy, and related disorders. RECENT
FINDINGS: In addition to its 'classic' role as an inhibitor of IFNgamma signaling, a number of new regulatory roles in IFNalpha and toll-like receptor signaling have been defined for SOCS1, and substantial progress has been made in identifying the factors that give rise to lethal inflammation in Socs1 neonatal mice. The aberrant transcriptional regulation of suppressor of cytokine signaling genes in myeloid leukemia and related proliferative disorders has also been further defined. Finally, positive signs have emerged in mice that exogenous delivery of SOCS3 may be of therapeutic value.
SUMMARY: Suppressor of cytokine signaling proteins have pivotal roles in attenuating cytokine and toll-like receptor signaling in myeloid cells. Understanding how defective suppressor of cytokine signaling activity contributes to inflammatory and malignant disease promises to create significant new therapeutic opportunities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17133094     DOI: 10.1097/00062752-200701000-00004

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  15 in total

Review 1.  TAM receptor signaling and autoimmune disease.

Authors:  Carla V Rothlin; Greg Lemke
Journal:  Curr Opin Immunol       Date:  2010-10-26       Impact factor: 7.486

Review 2.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

Review 3.  What can Sjögren's syndrome-like disease in mice contribute to human Sjögren's syndrome?

Authors:  Ammon B Peck; Cuong Q Nguyen
Journal:  Clin Immunol       Date:  2017-05-03       Impact factor: 3.969

4.  Severe Listeria monocytogenes infection induces development of monocytes with distinct phenotypic and functional features.

Authors:  Douglas A Drevets; Jennifer E Schawang; Vinay K Mandava; Marilyn J Dillon; Pieter J M Leenen
Journal:  J Immunol       Date:  2010-07-14       Impact factor: 5.422

5.  Tumor necrosis factor-a augments lipopolysaccharide-induced suppressor of cytokine signalling 3 (SOCS-3) protein expression by preventing the degradation.

Authors:  Jargalsaikhan Dagvadorj; Yoshikazu Naiki; Gantsetseg Tumurkhuu; Abu Shadat Mohammod Noman; Imtiaz Iftakhar-E-Khuda; Takayuki Komatsu; Naoki Koide; Tomoaki Yoshida
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

6.  High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector.

Authors:  Xiao-Bing Zhang; Brian C Beard; Grant D Trobridge; Brent L Wood; George E Sale; Reeteka Sud; R Keith Humphries; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.

Authors:  Ewa Kozela; Maciej Pietr; Ana Juknat; Neta Rimmerman; Rivka Levy; Zvi Vogel
Journal:  J Biol Chem       Date:  2009-11-12       Impact factor: 5.157

8.  SOCS1 is a negative regulator of metabolic reprogramming during sepsis.

Authors:  Annie Rocio Piñeros Alvarez; Nicole Glosson-Byers; Stephanie Brandt; Soujuan Wang; Hector Wong; Sarah Sturgeon; Brian Paul McCarthy; Paul R Territo; Jose Carlos Alves-Filho; C Henrique Serezani
Journal:  JCI Insight       Date:  2017-07-06

9.  Reduced SOCS1 Expression in Lung Fibroblasts from Patients with IPF Is Not Mediated by Promoter Methylation or Mir155.

Authors:  Cecilia M Prêle; Thomas Iosifidis; Robin J McAnulty; David R Pearce; Bahareh Badrian; Tylah Miles; Sarra E Jamieson; Matthias Ernst; Philip J Thompson; Geoffrey J Laurent; Darryl A Knight; Steven E Mutsaers
Journal:  Biomedicines       Date:  2021-04-30

Review 10.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

Authors:  Jianbiao Zhou; Boon-Cher Goh; Daniel H Albert; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2009-07-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.